Clinical data shows approximately 15% average weight loss in GLP-1 users over 68 weeks, but individual outcomes vary significantly based on metabolic profile, genetics, and lifestyle factors your provider must assess
However, the broader implications of its use are not yet fully understood
Critical uncertainties persist concerning ideal candidate identification, therapeutic sequence, combination strategies with other emerging MASH therapies, long-term durability of benefits, and cost-effectiveness
As hair is non-essential tissue, it is incredibly sensitive to internal fluxes particularly to our nutritional status, the trichologist says
This chapter primarily evaluates potential drugs for the treating of gout by targeting BA metabolism
With approved resmetirom, our patients with clinically significant scarring of the liver due to MASH will have access to an effective and approved therapeutic agent to reverse disease progression, Sanyal said
